代谢型谷氨酸受体基因的多态性对阿立哌唑疗效的影响

Effects of glutamate receptor gene polymorphism on efficacy of Aripiprazole

目的:探讨阿立哌唑治疗精神分裂症的疗效与代谢型谷氨酸受体-2(m GluR2)基因多态性的关系。方法:选择160例精神分裂症患者为研究组,并选择同期健康志愿者160例为对照组,应用阳性与阴性症状量表(PANSS)、临床总体印象量表-严重程度和改善程度量表(CGI-SI)分别于治疗前和治疗后2、4、8周对研究组患者进行疗效评定。采用DNA测序技术检测上述患者m GluR2基因单核苷酸多态性rs724226和rs1468412的基因型并分组研究,并对精神分裂症患者的谷氨酸受体基因多态性进行关联分析。结果:rs724226基因型的患者PANSS总分从治疗2周起开始显著下降,治疗前后差异有统计学意义(P<0.05或P<0.01);rs1468412的基因型的患者PANSS总分下降不明显,治疗前后差异无统计学意义(P>0.05)。结论:阿立哌唑治疗精神分裂症的疗效可能与谷氨酸受体基因的多态性有关。

Objective To investigate efficacy of Aripiprazole in treatment of schizophrenia and its relationship with metabo-ropic glutamate receptor-2 （mGluR2） gene polymorphism. Methods： 160 schizophrenic patients were selected as study group, while60 healthy volunteer at the same period were selected as control group. The efficacies were assessed with the positive and negativeymptom scale （PANSS） and the clinical global impression scale-severity of illness （CGI-SI） before and 2, 4 and 8 weeks after thereatment. The single nucleotide polymorphism of the mGluR2 gene of the patients with rs724226 and rs1468412 genotype was detectedy using DNA sequencing technique, and their relations with the glutamate receptor gene polymorphism were analyzed. Results： ThePANSS scores of the patients with rs724226 genotype began to decrease significantly from the 2nd treatment, and the differences withhose before the treatment were statistically significant （ P〈0.05 or P 〈0.01） . However, the PANSS scores of the patients withs1468412 genotype had no obvious decrease, and the differences with those before the treatment were not statistically significant （P〉0.05）. Conclusions ： The efficacy of Aripiprazole in the treatment of schizophrenia may be associated with the glutamate receptor geneolymorphism.